Business Context and Reporting Period
This Form 6-K/A filing by GlaxoSmithKline plc (GSK) covers the period ending January 2015. The document serves as a notification of transactions involving Persons Discharging Managerial Responsibilities (PDMRs) in accordance with DTR 3.1.4R(1)(a).
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. The document is limited to reporting specific share transactions and does not contain consolidated financial statements.
Material Changes
The filing reports increases in the actual interests of two PDMRs in American Depositary Shares (ADSs). These increases resulted from the re-investment of dividends paid on ADSs held in the vested portion of the GSK 2009 Deferred Annual Bonus Plan Post-Tax awards. The transactions occurred at a price of $41.78 per ADS.
- Mrs D P Connelly: Increase of 13.90 ADSs.
- Mr W C Louv: Increase of 36.55 ADSs.
Guidance, Outlook, and Risks
The filing text does not provide a clear value for guidance, outlook, management commentary, risks, contingencies, or unusual items. The document is strictly a regulatory notification of director shareholding changes.
Investor Verification Points
- Verify the total shareholding positions of Mrs D P Connelly and Mr W C Louv following these specific transactions.
- Confirm the terms of the GSK 2009 Deferred Annual Bonus Plan Post-Tax awards to understand the source of the dividend reinvestment.
- Review the market price of GSK ADSs on January 16, 2015, to validate the reported transaction price of $41.78.